2 weeks Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here’s What You Should Know Zacks

The consensus price target hints at a 45.9% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biomarin Pharma (BMRN) · Wall Street